Your browser doesn't support javascript.
loading
Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
Harris, Faye R; Zhang, Piyan; Yang, Lin; Hou, Xiaonan; Leventakos, Konstantinos; Weroha, Saravut J; Vasmatzis, George; Kovtun, Irina V.
  • Harris FR; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • Zhang P; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • Yang L; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • Hou X; Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Leventakos K; Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Weroha SJ; Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Vasmatzis G; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Kovtun IV; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Mol Oncol ; 13(2): 132-152, 2019 02.
Article en En | MEDLINE | ID: mdl-30499260
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor ErbB-2 / Ensayos Antitumor por Modelo de Xenoinjerto / Antineoplásicos Tipo de estudio: Guideline Límite: Animals / Female / Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor ErbB-2 / Ensayos Antitumor por Modelo de Xenoinjerto / Antineoplásicos Tipo de estudio: Guideline Límite: Animals / Female / Humans Idioma: En Año: 2019 Tipo del documento: Article